NVIDIA and Eli Lilly announced a $1 billion partnership to build an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The collaboration will combine NVIDIA’s computing and AI stack with Lilly’s drug‑discovery expertise to accelerate biologics and small‑molecule programs, and to develop tailored AI models for therapeutic design. Both partners described the effort as platform‑level investment rather than a single‑asset bet, aiming to scale discovery throughput and reduce preclinical timelines across multiple target classes.